Clinical trial
An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naïve and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients.
NCT01898364 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naïve and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients.
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 19, 2013
- Completion date
- February 25, 2015
- Enrollment
- 24 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
acid maltase deficiency, glycogen storage disease type ii (gsd ii), pompe disease